Clinical Trial Update: Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of ADV-specific T-cells in pediatric patients after allogeneic hematopoietic stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

Drugs mentioned

• ADV-specific T-cells (ADV-specific T-cells)

Snippet

Sponsor: Cell Medica Ltd | Conditions: ADV Infection Post Allo-HSCT | Phase 1, Phase 2 | Status: COMPLETED